Market Place
Sourcing Support
Immuthera Secure License for CD6/CTLA-4 CAR-Treg Platform
12 Jan 2026 //
PHARMIWEB
Dr. Adrian Bot Joins Immuthera To Drive Commercialization
07 Nov 2025 //
GLOBENEWSWIRE
PolTREG Injects First Patient in Phase Ii Trial
04 Aug 2025 //
GLOBENEWSWIRE
PolTREG, Immuthera Get Positive FDA Nod for Pre T1D Trial
31 Jul 2025 //
GLOBENEWSWIRE
Immuthera Appoints Top Experts to Scientific Advisory Board
04 Jul 2025 //
GLOBENEWSWIRE
PolTREG Forms U.S. Unit Immuthera for Global Expansion
13 Jun 2025 //
GLOBENEWSWIRE
EMA Approves PolTREG`s Treg Therapy for Type 1 Diabetes
15 May 2025 //
GLOBENEWSWIRE
PolTREG Launches Phase 2 Trial for Diabetes in Children
24 Oct 2024 //
GLOBENEWSWIRE
PolTREG Starts CAR-Treg Development For Autoimmune Diseases
26 Sep 2024 //
GLOBENEWSWIRE
China Patent Boosts PolTREG`s Treg Cell Therapy For Multiple Sclerosis
16 Sep 2024 //
GLOBENEWSWIRE
PolTREG Treg Cell Therapy Shows Remission In Type-1 Diabetes
09 Sep 2024 //
GLOBENEWSWIRE
PolTREG type-1 diabetes Treg cell therapy shows long-term safety and efficacy
24 Jun 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.